scholarly journals Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme

2004 ◽  
Vol 53 (6) ◽  
pp. 1018-1032 ◽  
Author(s):  
R. Reynolds
Keyword(s):  
Antimicrobial Susceptibility ◽  
Surveillance Programme ◽  
The Uk

scholarly journals Australian Meningococcal Surveillance Programme annual report, 2017

2019 ◽  
Vol 43 ◽  
Author(s):  
Monica M Lahra ◽  
Rodney Enriquez ◽  
CR Robert George
Keyword(s):  
South America ◽  
Antimicrobial Susceptibility ◽  
Molecular Typing ◽  
Surveillance System ◽  
Annual Report ◽  
Sequence Type ◽  
Age Group ◽  
Surveillance Programme ◽  
Encoding Gene ◽  
The Uk

In 2017, there were 374 laboratory-confirmed cases of invasive meningococcal disease (IMD) analysed by the Australian National Neisseria Network. This was the highest number of laboratory-confirmed cases since 2003. Probable and confirmed cases of IMD are notifiable in Australia; there were 379 IMD cases notified to the National Notifiable Diseases Surveillance System in 2017, the highest number reported since 2005. Meningococcal sero-grouping was determined for 98% (367/374) of laboratory-confirmed IMD cases. Serogroup B infections accounted for 137 cases (37%). The number of serogroup W infections (141 cases, 38%) in 2017 was the highest since the Australian Meningococcal Surveillance Programme (AMSP) began. In addition, the number and proportion of serogroup Y infections (75 cases, 20%) was also the highest recorded by the AMSP. Molecular typing results were available for 315 of the 374 IMD cases (83%). Of the serogroup W IMD strains that were able to be genotyped, 97% (125/129) had the PorA antigen encoding gene type P1.5,2 and of these, 59% (74/125) were sequence type 11, the same type as the hypervirulent serogroup W strain that has been circulating in the UK and South America since 2009. The primary IMD age peak was observed in adults aged 45 years or more, whilst secondary disease peaks were observed in those aged less than 5 years. Serogroup B infections predominated in the age group 15–19 years. Serogroup W infections predominated in those aged 65 years or more. Serogroup Y infections were predominately seen in adults aged 45 years or more. Of the IMD isolates tested for antimicrobial susceptibility, 5.1% (14/276) were resistant to penicillin; decreased susceptibility to penicillin was observed in a further 89% (247/276) of isolates. All isolates tested were susceptible to ceftriaxone; two isolates were less susceptible to ciprofloxacin; and one isolate was resistant to rifampicin.

scholarly journals Activity of ceftaroline versus ceftobiprole against staphylococci and pneumococci in the UK and Ireland: analysis of BSAC surveillance data

2020 ◽  
Vol 75 (11) ◽  
pp. 3239-3243
Author(s):  
Carolyne Horner ◽  
Shazad Mushtaq ◽  
David M Livermore ◽  
M Allen ◽  
D F J Brown ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Streptococcus Pneumoniae ◽  
Time Trend ◽  
High Dose ◽  
Good Activity ◽  
Surveillance Programme ◽  
Gram Negative ◽  
Methicillin Resistant ◽  
Agar Dilution ◽  
The Uk

Abstract Background Ceftaroline and ceftobiprole inhibit most MRSA and MDR pneumococci. Few direct comparisons of their activity have been published, but in several years (2008, 2013, 2017 and 2018) both were tested in parallel in the BSAC Resistance Surveillance Programme, giving paired results. These are reviewed. Methods Isolates included were bloodstream Staphylococcus aureus [n = 1884 (MRSA, n = 234)], bloodstream CoNS (n = 813; 574 methicillin resistant), and bloodstream (n = 852) and respiratory (n = 670) Streptococcus pneumoniae. MICs were determined by BSAC agar dilution and reviewed against EUCAST breakpoints; S. aureus breakpoints were assumed for CoNS. Results Ceftaroline MICs were mostly 2-fold lower than those of ceftobiprole, but, for all groups, MICs of both agents were strongly inter-related. Methicillin-susceptible staphylococci were universally susceptible to both agents; all MRSA were susceptible to ceftobiprole, whereas 10/234 had intermediate/high-dose susceptibility to ceftaroline. Among methicillin-resistant CoNS, 88% were susceptible to both agents, but reduced ceftaroline susceptibility and ceftobiprole resistance were frequent (65%) among methicillin-resistant Staphylococcus haemolyticus. One S. pneumoniae was resistant to both ceftaroline (MIC 0.5 mg/L) and ceftobiprole (MIC 1 mg/L) and seven others were only resistant to ceftobiprole (MIC 1 mg/L); seven of these eight pneumococci belonged to serotype 19A or 19F. No time trend in susceptibility was seen for either cephalosporin. Conclusions Ceftaroline and ceftobiprole have similarly good activity against staphylococci and pneumococci. Therapeutic choices between these agents should be predicated on other differentiating factors, including licensed indications, clinical experience and need for Gram-negative coverage.

Emergence of pneumococcal 19A empyema in UK children

2012 ◽  
Vol 97 (12) ◽  
pp. 1070-1072 ◽  
Author(s):  
Matthew F Thomas ◽  
Carmen L Sheppard ◽  
Malcolm Guiver ◽  
Mary P E Slack ◽  
Robert C George ◽  
...  
Keyword(s):  
Pneumococcal Disease ◽  
Pneumococcal Serotypes ◽  
Protection Agency ◽  
Surveillance Programme ◽  
Severity Of Disease ◽  
Serotype 1 ◽  
The Usa ◽  
Pneumococcal Serotype ◽  
The Uk ◽  
Substantial Morbidity

IntroductionInvasive pneumococcal disease due to serotype 19A has become a major concern, particularly in the USA and Asia. We describe the characteristics of pneumococcal serotype 19A related empyema and changes in its incidence in the UK.MethodsData from paediatric empyema patients between September 2006 and March 2011 were collected from 17 respiratory centres in the UK. Pneumococcal serotypes were identified as part of the Health Protection Agency enhanced paediatric empyema surveillance programme.ResultsFour serotypes accounted for over 80% of 136 cases (Serotype 1 : 43%, 3 : 21%, 7 : 11% and 19A:10%). The incidence of empyema due to serotype 19A quadrupled from 0.48 (0.16–1.13) cases per million children in 2006/2007 to 2.02 (1.25–3.09) in 2010/2011. Severity of disease was significantly increased in children with 19A infection when compared to other serotypes.ConclusionsThe incidence of empyema due to pneumococcal serotype 19A infection has increased significantly and is associated with substantial morbidity.

scholarly journals Make the Adder Count: population trends from a citizen science survey of UK adders

2019 ◽  
pp. 57-70 ◽  
Author(s):  
Emma Gardner
Keyword(s):  
Habitat Management ◽  
Extinction Risk ◽  
Large Population ◽  
Surveillance Programme ◽  
Large Populations ◽  
Management Plans ◽  
The Status ◽  
Priority Species ◽  
Negative Impacts ◽  
The Uk

Concern has been growing about the status of UK adder populations, with expert opinion reporting widespread declines. Assessing the true scale of these declines, however, has been hampered by a lack of quantitative data. Make the Adder Count began in 2005 as a national surveillance programme collecting standardised counts of adders lying-out after emerging from hibernation. 260 sites have contributed data, confirming a significant decline, on average, across sites with small populations, while the few with large populations (<10 % of sites) are weakly increasing. If these trends continue, within 15‒20 years, adders will be restricted to a few large population sites, significantly increasing the extinction risk for this priority species in the UK. Public pressure/disturbance was reported as the most frequent negative factor affecting sites, followed by habitat management and habitat fragmentation. Negative impacts from habitat management were reported almost as frequently as positive impacts, suggesting many management plans do not adequately consider the requirements of adders. The dataset also demonstrated earlier emergence among males, in warmer springs and at more northerly sites.

scholarly journals Australian Meningococcal Surveillance Programme Annual Report, 2020

2021 ◽  
Vol 45 ◽  
Author(s):  
Monica M Lahra ◽  
CR Robert George ◽  
Masoud Shoushtari ◽  
Tiffany R Hogan
Keyword(s):  
Nucleic Acid ◽  
Antimicrobial Susceptibility ◽  
Meningococcal Disease ◽  
Surveillance System ◽  
Annual Report ◽  
Bacterial Culture ◽  
Sequence Type ◽  
Nucleic Acid Amplification ◽  
Notifiable Disease ◽  
Surveillance Programme

Invasive meningococcal disease (IMD) is a notifiable disease in Australia, and both probable and laboratory-confirmed cases of IMD are reported to the National Notifiable Diseases Surveillance System (NNDSS). In 2020, there were 90 notifications of IMD, the lowest number documented since records began in the NNDSS in 1991. Of these, 97% (87/90) were laboratory-confirmed cases, with 70% (61/87) confirmed by bacterial culture and 30% (26/87) by nucleic acid amplification testing. The serogroup was determined for 85/87 laboratory-confirmed cases of IMD: serogroup B (MenB) accounted for 64% of infections (54/85); MenW for 19% (16/85); MenY for 16% (14/85); and MenC 1.2% (1/85). Fine typing was available on 60/85 (71%) of cases with serogroup determined; of the typed MenW, all were PorA antigen type P1.5,2 and sequence type 11, the hypervirulent strain reported in recent outbreaks in Australia and overseas. The primary peaks of IMD notifications in Australia in 2020 were observed in infants less than 1 year (16/87, 18%) and in adults aged 45–64 years (14/87, 16%). MenB infections predominated in those aged less than 5 years and 15–19 years; MenW and MenY infections predominated in those aged 45 years or more. All 61 IMD isolates were tested for antimicrobial susceptibility: none were penicillin resistant; however, 56/61 (92%) had decreased susceptibility to penicillin. All isolates were susceptible to ceftriaxone, ciprofloxacin and rifampicin.

The UK′s Food Chemical Surveillance Programme

1994 ◽  
Vol 96 (2) ◽  
pp. 24-29 ◽  
Author(s):  
David Atkins
Keyword(s):  
Surveillance Programme ◽  
The Uk

Antimicrobial susceptibility monitoring of canine and feline skin and ear pathogens isolated from European veterinary clinics: results of the ComPath Surveillance programme

2020 ◽  
Vol 31 (6) ◽  
pp. 431
Author(s):  
Anno Jong ◽  
Myriam Youala ◽  
Farid El Garch ◽  
Shabbir Simjee ◽  
Markus Rose ◽  
...  
Keyword(s):  
Antimicrobial Susceptibility ◽  
Surveillance Programme
Sign in / Sign up

Export Citation Format

Share Document